These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34052807)

  • 1. Causes and Consequences of Chronic Sleep Deficiency and the Role of Orexin.
    Mullington JM; Cunningham TJ; Haack M; Yang H
    Front Neurol Neurosci; 2021; 45():128-138. PubMed ID: 34052807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
    Sun Y; Tisdale RK; Kilduff TS
    Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
    Kumar A; Chanana P; Choudhary S
    Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
    Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
    ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.
    Bigalke JA; Shan Z; Carter JR
    Hypertension; 2022 Dec; 79(12):2643-2655. PubMed ID: 36148653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.
    Fragale JE; James MH; Avila JA; Spaeth AM; Aurora RN; Langleben D; Aston-Jones G
    Front Neurol Neurosci; 2021; 45():117-127. PubMed ID: 34052815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin Receptor Antagonism Improves Sleep and Reduces Seizures in Kcna1-null Mice.
    Roundtree HM; Simeone TA; Johnson C; Matthews SA; Samson KK; Simeone KA
    Sleep; 2016 Feb; 39(2):357-68. PubMed ID: 26446112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
    Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin Receptor Antagonists and Insomnia.
    Wu X; Xue T; Chen Z; Wang Z; Chen G
    Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
    Roecker AJ; Cox CD; Coleman PJ
    J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms.
    Tang S; Huang W; Lu S; Lu L; Li G; Chen X; Liu X; Lv X; Zhao Z; Duan R; Du Y; Tang J
    Peptides; 2017 Feb; 88():55-61. PubMed ID: 27988352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
    Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preface.
    Steiner MA; Yanagisawa M; Clozel M
    Front Neurol Neurosci; 2021; 45():IX-X. PubMed ID: 34052818
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
    Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
    Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis.
    Dong YJ; Jiang NH; Zhan LH; Teng X; Fang X; Lin MQ; Xie ZY; Luo R; Li LZ; Li B; Zhang BB; Lv GY; Chen SH
    Biomed Pharmacother; 2021 Nov; 143():112141. PubMed ID: 34509822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.